Health Care

Analyst Review on Buzzer: Astrazeneca PLC (NYSE:AZN)

0 5

Astrazeneca PLC (NYSE:AZN) surged +0.48% and closed the trade at $ 33.82. The company recorded a trading capacity of 5.15 million shares below its three months average daily volume of 6.26 million shares. During the last trade, shares reached to high price of $34.15 and touched the low price of $33.68. The stock’s 50-day moving average is noted at $33.40 and its 200-day moving average is stands at $30.24.

Additionally, the company has a PE ratio of 38.65 and has EPS of 0.88. The company has market capitalization of $85.56B.

Currently Astrazeneca PLC (AZN) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “12″ Analysts”. “3” rated “Sell” for the company. “14” said the company as a “Hold”. Overweight rating was given by “1” and Underweight rating was given by “1”.

Analysts are expecting that the company to achieve $34.66 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $46.53 however minimum price target advised by analysts is $25.92. The Median price target for the stock is measured at $34.48.

Presently, Analysts decided consensus EPS estimate of $0.57 for present quarter and one month ago projected EPS estimate was at $0.57. If we take a look at back 3 month ago, consensus EPS estimate was $0.52.

A current consensus EPS estimate for next quarter is at $0.59 and 3 month ago EPS forecast was $0.52. Have a look at back 1 month ago, consensus EPS forecast was seen at $0.59.

For current fiscal year, most recent EPS estimate is set at $2.11 based on Analyst consensus and three month ago consensus EPS opinions was at $1.97. During period one month ago, consensus EPS forecast was decided at $2.03.

A current consensus EPS projection for next fiscal year is observed at $2.05 and one month ago consensus EPS forecast was at $1.96. Take a look at back three month ago, consensus EPS estimate opinions was decided at $1.94 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 13 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 1. 13 advised the “Hold” rating about this stock. 3 revealed “Sell” signal and “Underweight” rating was declared by 1.

Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 16 said a “Buy Rating” and 3 announced “Overweight Rating”. 11 advised “Hold Rating” regarding the stock. 3 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.